GSC
AGIO icon

Ground Swell Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Ground Swell Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,347
Closed -$282K – 149
2026
Q1 		$282K Buy
+8,347
New +$237K 0.56% 38
2014
Q3 		$2K Buy
+27
New +$1.16K ﹤0.01% 1856

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Ground Swell Capital's AGIO Position: Q2 2026 in Review

Ground Swell Capital sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 8,347 shares — an estimated $282K sold.

Ground Swell Capital first reported a position in AGIO in Q3 2014 and held it in 2 quarters. The position peaked at $282K in Q1 2026. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Ground Swell Capital reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ground Swell Capital sold 8,347 Agios Pharmaceuticals shares in Q2 2026, an estimated $282K.
  • Ground Swell Capital first reported a position in Agios Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Ground Swell Capital's Agios Pharmaceuticals position peaked at $282K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Ground Swell Capital's 13F filing for Q2 2026, filed 5 Aug 2026.